DBV Technologies gets Buy rating after Phase 3 Viaskin Peanut data

An analyst set a fair value estimate of $42 per ADS after positive late-stage trial results for the peanut allergy patch in children.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.